| Literature DB >> 25303960 |
Masakazu Nagafuku1, Takashige Sato2, Saya Sato1, Kyoko Shimizu3, Toshio Taira3, Jin-Ichi Inokuchi4.
Abstract
Ganglioside GM3 (Siaα2-3Galβ1-4Glcβ1-1Cer) has been known to participate in insulin signaling by regulating the association of the insulin receptor in caveolae microdomains (lipid rafts), which is essential for the execution of the complete insulin metabolic signaling in adipocytes. Macrophage-secreted factors including proinflammatory cytokines, tumor necrosis factor-α and interleukin-1β, in adipose tissues have been known to limit the local adipogenesis and induce insulin resistance; however, the interplay between adipocytes and macrophages upon regulation of GM3 expression is not clear. GM3 was virtually absent in primary adipocytes differentiated from macrophage-depleted mesenteric stromal vesicular cells, which accompanies enhancement of insulin signaling and adipogenesis. We found that the expression of GM3 is governed by soluble factors including steady-state levels of proinflammatory cytokines secreted from resident macrophages. The direct involvement of GM3 in insulin signaling is demonstrated by the fact that embryonic fibroblasts obtained from GM3 synthase (GM3S)-deficient mice have increased insulin signaling, when compared with wild-type embryonic fibroblasts, which in turn leads to enhanced adipogeneis. In addition, GM3 expression in primary adipocytes is increased under proinflammatory conditions as well as in adipose tissue of diet-induced obese mice. Moreover, GM3S-deficient mice fed high-fat diets become obese but are resistant to the development of insulin resistance and chronic low-grade inflammatory states. Thus, GM3 functions as a physiological regulatory factor of the balance between homeostatic and pathological states in adipocytes by modulating insulin signaling in lipid rafts.Entities:
Keywords: GM3 ganglioside; adipogenesis; inflammatory cytokines; insulin resistance; macrophages
Mesh:
Substances:
Year: 2014 PMID: 25303960 DOI: 10.1093/glycob/cwu112
Source DB: PubMed Journal: Glycobiology ISSN: 0959-6658 Impact factor: 4.313